Market closed
Esperion Therapeutics/$ESPR
Esperion Therapeutics shares are trading higher after the company announced a settlement agreement delaying a generic version of its drug NEXLETOL until Apr. 2040.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Esperion Therapeutics
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Ticker
$ESPR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
304
ISIN
US29664W1053
Website
ESPR Metrics
BasicAdvanced
$145M
-
-$0.81
0.75
-
Price and volume
Market cap
$145M
Beta
0.75
52-week high
$3.39
52-week low
$0.72
Average daily volume
6.2M
Financial strength
Current ratio
1.176
Quick ratio
0.723
Long term debt to equity
-112.45
Total debt to equity
-152.091
Interest coverage (TTM)
-0.62%
Management effectiveness
Return on assets (TTM)
-7.17%
Return on equity (TTM)
42.53%
Valuation
Price to revenue (TTM)
0.545
Price to book
-0.34
Price to tangible book (TTM)
-0.34
Price to free cash flow (TTM)
-1.41
Growth
Revenue change (TTM)
12.99%
Earnings per share change (TTM)
18.07%
3-year revenue growth (CAGR)
42.71%
3-year earnings per share growth (CAGR)
-49.33%
What the Analysts think about ESPR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Esperion Therapeutics stock.
ESPR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ESPR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ESPR News
AllArticlesVideos
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewsWire·4 days ago
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
GlobeNewsWire·7 days ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Esperion Therapeutics stock?
Esperion Therapeutics (ESPR) has a market cap of $145M as of May 16, 2025.
What is the P/E ratio for Esperion Therapeutics stock?
The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of May 16, 2025.
Does Esperion Therapeutics stock pay dividends?
No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Esperion Therapeutics dividend payment date?
Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Esperion Therapeutics?
Esperion Therapeutics (ESPR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.